An exploratory clinical trial on the efficacy and safety of glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes on maintenance hemodialysis

• Material Type: 博士論文
• Title: An exploratory clinical trial on the efficacy and safety of glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes on maintenance hemodialysis
• Author/Editor: Ugamura, Daisuke
• Author Heading: Ugamura, Daisuke
• Publication Date: 2022-09-20
• Publication Date (W3CDTF): 2022-09-20
• Alternative Title: インスリン使用中の維持血液透析患者におけるGLP-1受容体作動薬デュラグルチドの併用によるその有効性および安全性に関する探索的臨床研究
• Degree grantor/type: 新潟大学
• Date Granted: 2022-09-20
• Date Granted (W3CDTF): 2022-09-20
• Dissertation Number: 甲第5074号
• Degree Type: 博士（医学）
• Text Language Code: eng
• Alias of Author: 宇賀村, 大亮
• Subject Heading: Dulaglutide; Glucagon-like peptide-1 receptor agonist; Hemodialysis; Once-weekly; Type 2 diabetes mellitus
• Target Audience: 一般
• Note (General): Background: Dulaglutide is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus (T2DM). However, the efficacy and safety of dulaglutide remain unclear in insulin-treated patients with T2DM on maintenance hemodialysis (HD). Methods: Dulaglutide treatment was initiated, and the insulin dose was adjusted according to the needs of individual participants. Primary outcomes were changes in the mean and standard deviation (SD) of blood glucose (BG) levels and mean amplitude of glycemic excursions (MAGE) evaluated by continuous glucose monitoring (CGM) for six days, glycated albumin (GA), glycated hemoglobin (HbA1c), pre-dialysis blood glucose levels, and daily total insulin dose from the baseline over 24 weeks. Secondary outcomes were changes in treatment satisfaction and QOL levels from the baseline, measured by using the Diabetes Treatment Satisfaction Questionnaire (DTSQ) and the Diabetes Therapy-Related Quality of Life questionnaire (DTR-QOL) scores. Results: The analysis was performed on the 12 participants who completed the study. The GA level (median-1.8 [interquartile range-6.6,-0.3] %; p=0.026) and daily total insulin dose (-15.0 [-24.5,-9.4] U/day; p=0.002) significantly decreased without increasing hypoglycemia (area over the glucose curve < 70 mg/dl: 0.0 [-0.2, 0.0] mg・24 h/dl; p=0.917). Four patients successfully withdrew from insulin therapy. The levels of HbA1c, SD of BG, and MAGE showed a decreasing tendency, but no significant improvement. Regarding treatment satisfaction and QOL, the total scores of DTSQ (8.0 [0.3, 12.5]; p=0.041) and DTR-QOL (15.5 [-1.8, 42.0]; p=0.023) significantly improved. Conclusion: Dulaglutide may help improve glycemic control, treatment satisfaction, and QOL without increasing hypoglycemia in insulin-treated patients with T2DM on maintenance HD.; Renal Replacement Therapy. 2022, 8, 26.; 新大院博(医)第1087号
• Persistent ID (NDL): info:ndljp/pid/12864349; https://dl.ndl.go.jp/pid/12864349
• Collection: 障害者向け資料
• Collection (Materials For Handicapped People:1): テキストデータ
• Collection (particular): 国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文; https://dl.ndl.go.jp/collections/A00014
• Acquisition Basis: 博士論文（自動収集）
• Date Accepted (W3CDTF): 2023-05-05T22:12:37+09:00
• Format (IMT): application/pdf
• Access Restrictions: 国立国会図書館内限定公開
• Service for the Digitized Contents Transmission Service: 図書館・個人送信対象外
• Availability of remote photoduplication service: 可
• Periodical Title (URI): http://hdl.handle.net/10191/0002000966; https://niigata-u.repo.nii.ac.jp/records/2000966
• Data Provider (Database): 国立国会図書館 : 国立国会図書館デジタルコレクション; https://dl.ndl.go.jp